Nagrestipen, a variant of the human macrophage inflammatory protein-1 alpha (MIP-1α), also referred to as ECI 301, exhibits antitumor activity. It is employed in therapeutic trials focused on cancer, assessing its efficacy in the contexts of tumors, metastasis, radiation oncology, and the analysis of tumor metastasis [1].

Nagrestipen（ECI 301）（静脉注射；2μg；连续5天）在6Gy局部辐射肿瘤部位时显著抑制了雄性BALB/c小鼠的肿瘤生长，并增强了辐射的远处隔膜效应[1]。在雌性C57BL/6带LLC细胞的小鼠中，Nagrestipen（ECI 301）（静脉注射；0.08、0.4、2μg；第1、8、15天）能在辐照和未辐照部位以剂量依赖性方式抑制肿瘤生长[1]。